Brokers Set Expectations for Humana’s Q4 Earnings (NYSE:HUM)

Humana Inc. (NYSE:HUM) – Zacks Research increased their Q4 2026 earnings per share estimates for Humana in a report released on Tuesday, July 14th. Zacks Research analyst Team now anticipates that the insurance provider will post earnings per share of ($6.07) for the quarter, up from their prior estimate of ($6.08). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Humana’s current full-year earnings is $9.04 per share. Zacks Research also issued estimates for Humana’s Q4 2027 earnings at ($1.91) EPS.

A number of other equities research analysts have also weighed in on the stock. Royal Bank Of Canada raised their price target on shares of Humana from $246.00 to $415.00 and gave the company a “sector perform” rating in a report on Thursday, July 9th. JPMorgan Chase & Co. upped their price objective on shares of Humana from $214.00 to $316.00 and gave the company a “neutral” rating in a research report on Monday, June 8th. Wells Fargo & Company upgraded Humana from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $227.00 to $502.00 in a research note on Monday. Jefferies Financial Group raised Humana from a “buy” rating to a “buy” rating in a research report on Wednesday, May 20th. Finally, Needham & Company LLC initiated coverage on Humana in a report on Wednesday, May 20th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus target price of $325.87.

Humana Trading Up 0.1%

NYSE HUM opened at $406.98 on Thursday. The stock has a market cap of $48.86 billion, a P/E ratio of 43.53, a PEG ratio of 2.32 and a beta of 0.71. The company’s fifty day simple moving average is $348.73 and its 200-day simple moving average is $258.30. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. Humana has a 52 week low of $163.11 and a 52 week high of $415.00.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The firm had revenue of $39.65 billion during the quarter, compared to analysts’ expectations of $39.37 billion. During the same quarter in the prior year, the business earned $11.58 EPS. Humana’s quarterly revenue was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Montag A & Associates Inc. increased its position in shares of Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after purchasing an additional 94 shares during the last quarter. CoreCap Advisors LLC lifted its position in shares of Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Fideuram Asset Management Ireland dac acquired a new position in Humana in the fourth quarter worth about $27,000. Reflection Asset Management acquired a new position in Humana in the fourth quarter worth about $29,000. Finally, Rosenberg Matthew Hamilton increased its holdings in Humana by 136.0% in the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after buying an additional 68 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Zacks Research upgraded Humana (HUM) to strong-buy, signaling improved analyst confidence in the insurer’s outlook. Zacks upgrade report
• Positive Sentiment: Zacks Research raised earnings estimates across several periods, including FY2026 EPS to $9.04 and FY2027 EPS to $13.30, reinforcing the view that Humana’s earnings may improve materially over the next few years.
• Positive Sentiment: Truist Financial increased its price target on Humana to $415, close to the stock’s recent trading range, which can help validate the current rally. Truist price target raise
• Neutral Sentiment: Investors are also weighing commentary about whether Humana is already fully valued after its recent run, which may limit upside unless upcoming results confirm the improved earnings outlook. Yahoo Finance valuation article
• Neutral Sentiment: One article argues that Humana’s Q2 earnings need to catch up with the stock’s performance, meaning the market may be awaiting confirmation from the upcoming report before pushing the shares much higher. Seeking Alpha article
• Negative Sentiment: News that Humana’s agreement with Wexner Medical Center is set to end in October, and another report that its insurance network is terminating an agreement with Ohio State, could raise concerns about network disruption or member retention. Wexner Medical Center agreement article

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.